The FDA was not created in a single moment. It grew out of a 19th-century chemistry lab, was reshaped by two of the deadliest drug safety failures in U.S. history, and has been amended by Congress dozens of times since. This is the short version of how it got here, and how the laws it enforces actually fit together.
Before 1906: a chemistry lab, not an agency
The federal government's role in food and drug safety started small. As early as 1848, it began using chemical analysis to check imported drugs for adulteration. In 1862, that work landed inside the newly created Department of Agriculture, first as a Chemical Division and later reorganized as the Bureau of Chemistry. Its chief chemist, Harvey Washington Wiley, spent years building the scientific and political case for a national food and drug law, and is generally credited as the driving force behind the law that followed.
1906: The Pure Food and Drugs Act
Congress passed the Pure Food and Drugs Act, often called the Wiley Act, on June 30, 1906, and President Theodore Roosevelt signed it. Enforcement sat with Wiley's Bureau of Chemistry, still inside the Department of Agriculture. The law prohibited interstate commerce in adulterated or misbranded food and drugs, and gave the federal government power to examine samples, investigate violations, seize unlawful products, pursue criminal charges, and block unlawful imports.
It was, by design, narrower than what came later. The 1906 Act generally did not require proof that a new drug was safe before it reached the market, did not create a premarket approval process, did not regulate cosmetics, and did not treat medical devices as a distinct category. A 1911 Supreme Court decision, United States v. Johnson, narrowed it further by limiting the law's reach over false therapeutic claims to only the product's identity, not whether it actually worked. Congress responded with the Sherley Amendment of 1912, but that fix still required the government to prove a false claim was made with fraudulent intent, a high bar that left patients exposed to confidently marketed products that simply did not do what they claimed.
From bureau to agency
The agency's name changed twice before it became what we call it today. In 1927, the regulatory half of the Bureau of Chemistry's work was split off into a new unit called the Food, Drug, and Insecticide Administration, separating enforcement from the Department of Agriculture's research functions. In 1930, that unit was renamed the Food and Drug Administration, the name that has stuck ever since.
1937: the disaster that rewrote the law
In 1937, a Tennessee drug company sold a liquid form of the antibiotic sulfanilamide, marketed as Elixir Sulfanilamide, without any safety testing. Its solvent, diethylene glycol, is toxic to humans. More than 100 people died, many of them children. Because the 1906 Act had no premarket safety requirement, the company had broken no law by selling it; FDA could only act because the product was also misbranded, calling itself an "elixir," a term that technically implied it contained alcohol, which it did not. That legal technicality, not the deaths themselves, was the only hook available for a recall.
The public outcry accelerated a food and drug bill that had already been stalled in Congress for five years. Congress passed the Federal Food, Drug, and Cosmetic Act (the FD&C Act) on June 25, 1938, and it became effective on June 25, 1939, replacing the 1906 Act. It was a substantial expansion of federal authority: for the first time, new drugs required evidence of safety before they could be marketed; regulation extended to cosmetics and medical devices; labeling rules were tightened; and FDA gained the authority to conduct factory inspections.
Where the agency has lived
FDA's home within the federal government has moved several times, generally following broader government reorganizations rather than anything specific to FDA itself. It left the Department of Agriculture in 1940 for the newly created Federal Security Agency. That agency was renamed the Department of Health, Education, and Welfare (HEW) in 1953. When HEW split into separate departments in 1979, FDA landed in the newly formed Department of Health and Human Services (HHS), where it remains today. In 1988, the Food and Drug Administration Act formally established FDA in statute as an HHS agency led by a Commissioner appointed by the President.
Major amendments since 1938
The 1938 Act has been amended dozens of times. These are the ones most relevant to how the agency works today.
1941 & 1945 — Insulin and Penicillin Amendments
Required FDA to test and certify the purity and potency of every batch of insulin, then penicillin and other early antibiotics, before sale.
1951 — Durham-Humphrey Amendment
Created the legal line between prescription drugs and over-the-counter drugs, and set rules for prescription refills and labeling.
1962 — Kefauver-Harris Amendment
Passed after the thalidomide crisis, in which the drug caused severe birth defects in thousands of children in Europe; it was kept off the U.S. market largely due to the skepticism of FDA reviewer Dr. Frances Kelsey. The amendment required, for the first time, proof of effectiveness in addition to safety, introduced the modern informed-consent standard for clinical trials, and gave FDA authority over prescription drug advertising.
1976 — Medical Device Amendments
Created the modern device classification system (Class I, II, and III) and premarket review pathways, closing a long-standing gap in which devices had faced far less scrutiny than drugs.
1983 — Orphan Drug Act
Created financial incentives, including tax credits and market exclusivity, to encourage development of treatments for rare diseases that would otherwise attract little commercial interest.
1984 — Hatch-Waxman Act
Formally the Drug Price Competition and Patent Term Restoration Act. Created the modern generic drug approval pathway (the Abbreviated New Drug Application, or ANDA), while extending patent terms for brand-name manufacturers to offset time lost to FDA review.
1990 — Safe Medical Devices Act
Added device tracking and adverse event reporting requirements after a series of device-related injuries drew scrutiny to post-market oversight.
1992 — Prescription Drug User Fee Act (PDUFA)
Allowed FDA to collect fees from drug manufacturers to fund faster reviews. PDUFA has been renewed roughly every five years since, and similar user-fee programs now exist for medical devices (MDUFA), generic drugs (GDUFA), and biosimilars (BsUFA).
2007 — FDA Amendments Act (FDAAA)
Expanded FDA's post-market safety authority, created Risk Evaluation and Mitigation Strategies (REMS) for higher-risk drugs, and required many clinical trials to register on ClinicalTrials.gov.
2009 — Family Smoking Prevention and Tobacco Control Act
Gave FDA regulatory authority over tobacco products for the first time.
2010 — Biologics Price Competition and Innovation Act (BPCIA)
Passed as part of the Affordable Care Act, this created the abbreviated approval pathway for biosimilars, the biologic equivalent of generic drugs.
2016 — 21st Century Cures Act
Introduced the Breakthrough Devices Program, encouraged the use of real-world evidence in regulatory decisions, and pushed patient input further into the drug development process.
2022 — Modernization of Cosmetics Regulation Act (MoCRA)
The first significant expansion of FDA's cosmetics authority since the original 1938 Act. Added mandatory facility registration, adverse event reporting, and, for the first time, mandatory recall authority for cosmetics.
How the law actually fits together
It helps to know how these laws connect to the regulations companies work with day to day, since the terms get used loosely.
Congress writes and passes a statute, such as the FD&C Act. The 1938 Act, for example, was first published in the Statutes at Large as Chapter 675, 52 Stat. 1040, then reorganized by subject into Title 21 of the United States Code (21 U.S.C.), which incorporates all the amendments described above. The statute itself doesn't spell out every technical detail; instead, it authorizes FDA to issue regulations, which go through a public rulemaking process (a proposed rule in the Federal Register, a public comment period, then a final rule) before being incorporated into Title 21 of the Code of Federal Regulations (21 CFR). For example, the statute simply says a drug is adulterated if it isn't manufactured properly; FDA's CGMP regulations in 21 CFR Parts 210 and 211 spell out exactly what "properly" requires.
FDA guidance documents sit a level below that. They describe the agency's current thinking or recommended approach, but generally don't carry the same binding legal force as the statute or the CFR. In order of legal authority, it runs: the U.S. Constitution, then federal statutes in the U.S. Code, then federal regulations in the CFR, then agency guidance. A regulation has to be authorized by, and stay consistent with, the statute that created it; a court can strike down a regulation that oversteps what Congress actually authorized.
That's the federal layer on its own. In practice, a company also has to account for state, county, and city rules layered on top of it — our Regulatory Compliance Hierarchy case study (PDF) walks through a full real-world example using California and San Diego.
Want to talk through how any of this history shapes a current compliance question? Get in touch.